Sovateltide

Endothelin Receptor Agonist PeptideRx: InvestigationalCompound: Investigational

Also known as: Endotel, IRL-1620, PMZ-1620

Educational Only — Not medical advice. Consult a qualified clinician before using any peptide.

Summary

Sovateltide (IRL-1620) is a synthetic endothelin B receptor agonist under clinical investigation primarily for acute ischemic stroke. It has demonstrated neuroprotective and neurorestorative effects in preclinical models and has completed Phase II/III trials in India, showing improvements in neurological outcomes when administered adjunctively with standard thrombolytic therapy.

Mechanism of Action

Selective agonist of endothelin B (ETB) receptors; promotes neuroregeneration and angiogenesis by stimulating neural stem cell differentiation, oligodendrocyte precursor cell proliferation, and cerebral microvascular remodeling following ischemic injury

Routes of Administration

Intravenous

Goals & Uses

  • Reduction of infarct volumeNeuroprotectionLow
  • Neurological recovery after acute ischemic strokeNeuroprotection / NeurorestorationModerate
  • Promotion of neurogenesisNeuroregenerationModerate
  • Cerebral angiogenesisVascular RemodelingLow

Contraindications

  • Known hypersensitivity to sovateltide or excipientsAllergy/ImmunologyHigh
  • Severe hepatic impairmentOrganModerateLiver function concerns
  • Hemorrhagic strokeNeurologicalHigh

Adverse Effects

  • Injection site reactionsLocalUncommon
  • HeadacheNeurologicCommonPain in the head or upper neck
  • NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
  • Transient hypotensionCardiovascularUncommon

Drug Interactions

  • Tissue plasminogen activator (tPA / alteplase)Low
  • Antihypertensive agentsModerate
  • Endothelin receptor antagonists (e.g., bosentan, ambrisentan)High

Population Constraints

  • Patients with active malignancyOncologyRelative
  • Severe renal impairmentOrgan ImpairmentRelative
  • Pediatric patientsAgeRelative
  • Pregnant womenReproductiveRelative

Regulatory Status

  • European UnionInvestigationalNo EMA approval reported as of knowledge cutoff
  • United StatesInvestigationalIND-stage; not yet approved by FDA; being evaluated for ischemic stroke

Has received regulatory approval in India (CDSCO) for acute ischemic stroke as an adjunct to standard of care. Designated as an investigational new drug (IND) in the US context. Developed by Pharmazz Inc. Phase III trial results reported from India.

Evidence & Sources

No sources recorded yet.

Browse All PeptidesBuild My Stack